stockrowProQR Therapeutics N.V.
PRQRProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024.
- Revenue
- +135.0%
- EPS
- +28.6%
- Free cash flow
- −1.06%
- Total debt
- +8.71%
Quarter to June 2026, against a year earlier
Follow PRQR
Alert me
ProQR Therapeutics N.V. (PRQR) EV/Sales
As of 6 November 2026, ProQR Therapeutics N.V. (PRQR) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from −32.8× (May 2022) to 45.6× (December 2022); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.6× | 76.92% |
| FY2024 | 3.7× | (44.22%) |
| FY2023 | 6.7× | (81.30%) |
| FY2022 | 35.6× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | (33.50%) |
| Mar 2026 | 5.5× | (16.06%) |
| Dec 2025 | 6.6× | 2.37% |
| Sep 2025 | 6.4× | 29.52% |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RNA Atrium Therapeutics, Inc. compare | −4.3× |
| KROS Keros Therapeutics, Inc. compare | −1.3× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| CGEN Compugen Ltd. compare | 0.8× |
| PRQR ProQR Therapeutics N.V. | 1.1× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)